Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Research & Development: 2010-2025

Historic Research & Development for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $174.7 million.

  • Arrowhead Pharmaceuticals' Research & Development rose 28.61% to $174.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $607.2 million, marking a year-over-year increase of 20.02%. This contributed to the annual value of $607.2 million for FY2025, which is 20.02% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Research & Development of $174.7 million as of Q3 2025, which was up 7.59% from $162.4 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Research & Development ranged from a high of $174.7 million in Q3 2025 and a low of $44.7 million during Q1 2021.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Research & Development value was $133.1 million (recorded in 2025), while the average stood at $125.7 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Research & Development skyrocketed by 82.13% in 2021, and later declined by 1.45% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Research & Development (Quarterly) stood at $65.8 million in 2021, then rose by 27.26% to $83.7 million in 2022, then skyrocketed by 39.19% to $116.5 million in 2023, then increased by 17.61% to $137.0 million in 2024, then rose by 28.61% to $174.7 million in 2025.
  • Its Research & Development stands at $174.7 million for Q3 2025, versus $162.4 million for Q2 2025 and $133.1 million for Q1 2025.